Northwire Canada EditionMonday, July 13, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Other

Aurora Expands Leading Portfolio of High-Potency Medical Flower Products in Poland

By The Northwire Desk — AI Analysis Dec 11, 2025 · 07:00 ACB · 6.26 AURORA CANNABIS INC. J
ACB · Price

Executive Summary

  • Aurora Cannabis announced the launch of a new high‑potency medical cannabis cultivar, Black Jelly, in Poland, expanding its product portfolio in one of Europe’s fastest‑growing markets.
  • Black Jelly offers a THC concentration of 27% (CBD <1%) and is derived from Aurora’s proprietary genetics (Alien Cake 3030 × T037).
  • The cultivar is immediately available to Polish prescribers, reinforcing Aurora’s strategy to increase market share in European medical cannabis.

Key Details

  • Product: Black Jelly – proprietary high‑THC sativa cultivar.
  • Cannabinoid Profile: THC 27% / CBD <1%.
  • Genetic Lineage: Derived from Alien Cake 3030 × T037.
  • Availability: Effective December 11, 2025 for all Polish medical prescribers.
  • Production Standards: Grown and processed in Aurora’s Canadian GACP‑certified and EU‑GMP‑certified facilities; utilizes premium hang‑drying and curing techniques.
  • Brand Positioning: Joins existing Aurora flos products Farm Gas and Sourdough under the Aurora medical cannabis brand portfolio.
  • Strategic Rationale: Enhances Aurora’s high‑potency offering to meet prescriber demand for reliable, potent medical cannabis in Poland; supports broader European market growth objectives.

Notable Quotes

“Aurora is uniquely positioned to bring this novel proprietary cultivar to the Polish market thanks to the company’s advanced genetic breeding program and unmatched global cultivation excellence,” – Andreas Dotterweich, Senior Vice President, Aurora Europe.

Materiality Assessment: Material – Positive (the launch represents a significant expansion of Aurora’s product line in a key European market, likely to impact revenue and market positioning).

Read the original news release →

More from AURORA CANNABIS INC. J

Jun 11, 2026 · 07:05

Record FY2026 revenue masks structural margin contraction and explicit FY2027 guide-cut; cash-rich but capital allocation remains dilutive.

Earnings May 14, 2026 · 08:45

Aurora Cannabis Secures IP Rights Amidst Sector Consolidation and Price Stabilization

M&A / Property May 14, 2026 · 06:54

Aurora Secures IP Moat Amidst Dilution Concerns and Cash Burn

M&A / Property Apr 28, 2026 · 15:57

Aurora Cannabis Expands Global Medical Portfolio Amidst Dilution Concerns and Profitability Push

Production / Operations Apr 28, 2026 · 06:53

Product Expansion Validates EU Capacity Play, But Dilution Risk Looms Over Cash Burn

Production / Operations Apr 15, 2026 · 07:05

Aurora Cannabis Acquires EU GMP Capacity Amidst Stock Decline

M&A / Property